Sarcoma News and Research

RSS

First Edition: February 16,2012

Today's early morning highlights from the major news organizations include the latest reports on congressional efforts to block a cut in Medicare payments to doctors.

16 Feb 2012

Eighth grader develops AnimalGrams to support pediatric cancer research at UCLA

When he was 11, Cameron Cohen created the hit drawing app iSketch for the iPhone and donated $20,000 of the proceeds from its sales to the Chase Child Life program at Mattel Children's Hospital UCLA.

10 Feb 2012

DF/CHCC specialists recommend genetic counseling for children with Li-Fraumeni syndrome

Genetic specialists at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person's risk of developing additional cancers.

9 Feb 2012

Successful six organ transplants in 9 year old

A 9 year old girl from Maine is making recovery days after surgeons transplanted six of her organs in a groundbreaking medical procedure.

6 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

3 Feb 2012

New initiative to detect cancers in earliest stages inside cells

A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers.

29 Dec 2011

New UA cancer research centre to focus on personalised treatment options

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

20 Dec 2011

Individualised approach to cancer medicine considering genetic variations

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

19 Dec 2011

Researchers discover novel viral oncogenesis mechanism

Human tumor viruses contribute to 15-20% of human cancers worldwide. Kaposi's sarcoma herpesvirus (KSHV) is an etiological agent for Kaposi's sarcoma (KS) and two other rare lymphoproliferative malignancies. KS is the most common cancer in HIV-infected untreated individuals and remains a primary cause of cancer deaths in many subequatorial African countries as a result of the AIDS pandemic.

15 Dec 2011

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California.

7 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

Promising new agent against sarcomas affecting children

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.

3 Dec 2011

MK 1775 shows promise against sarcomas

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla.

3 Dec 2011

Joslin study uncovers potential targets for soft-tissue sarcomas

Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.

30 Nov 2011

IRCI to design and fund clinical trials for rare cancers

Cancer Research UK will join forces with international research groups from the UK, Europe and the US to launch an initiative to boost the development of new treatments for patients with rare cancers. The announcement will be made by Dr Harpal Kumar, chief executive of Cancer Research UK, at the 2011 World Cancer Leaders' Summit taking place today in Dublin.

18 Nov 2011

Cancer drug joins list of medicines in short supply

A crucial cancer drug has been in short supply since midsummer - and its maker, Johnson & Johnson Inc., has not been able to remedy the situation since.

14 Nov 2011

First Edition: November 14, 2011

In today's headlines, reports about the Supreme Court's expected health law announcement; about where things stand with the super committee and its fast-approaching deadline; and other health policy news.

14 Nov 2011

Stem cell markers can aid in determining origin of pediatric sarcomas

The authors of a report in the current issue of the journal Pediatric and Developmental Pathology sought to use stem cell markers as an aid in determining the cell of origin. The expression of stem cell-associated proteins shows differences that can help identify how the tumors evolve. Eighty-one tumors were analyzed, all diagnosed in patients under 18 years old.

10 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011